TickerTalks
Browse all tickers →
TickerTalks›$KLRA
KLKLRA

Kailera Therapeutics, Inc.

$KLRA·$1.3B·Biotechnology·Healthcare
$10.53-2.8%1Y-58.3%
Price updated 4h ago·X counts updated 3d ago
KLKLRA
$KLRAKailera Therapeutics, Inc.
$10.53-2.77%44 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $KLRA on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

44X posts · last 7 days
Sep 21Oct 4
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $KLRA's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Bullish sentiment⚠AI analysisGenerated by AI from underlying data5 posts analyzed · as of 2026-08-26 · top-engagement diverged

Kallyope Therapeutics chatter is quietly bullish. Royalty Pharma Sub-Manager and Atlas Venture Life Science Advisors both opened new positions in Q2, and KLRA appears on a list of biopharma names with the largest net increases in specialist holders. A minority notes a 1.4% Phase 3 discontinuation rate hides a 19.9% dose reduction rate at 6mg due to TEAEs. Tone is small but confident specialist-holder accumulation.

Read what X is saying about $KLRA

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $KLRA — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-10-03

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Kailera's GLP-1/GIP ribupatide completed Phase 3 enrollment with specialist holders stacking — the readout is where the thesis resolves.

Kailera Therapeutics is a clinical-stage obesity/metabolic biopharma whose lead asset ribupatide (GLP-1/GIP dual agonist) just completed enrollment in the KaiNETIC Global Phase 3 program. Specialist biotech investors (Royalty Pharma Sub-Manager, Atlas Venture Life Science Advisors) opened new positions in Q2.

  • The P&L is literally pre-revenue: zero quarterly revenue with EPS of -$0.67 — this is a biotech whose stock price is driven by trial progress and specialist-holder signaling, not by quarterly operations.
  • The specific catalyst stack is clean: EASD 2026 clinical data presentation, Phase 3 enrollment completion, and the biopharma specialist-holder increase list — plus the specific competitive context of Novo being 'open to acquisitions' with Kailera named as a potential candidate.

The 1.4% Phase 3 discontinuation rate is a legitimate honest flag — but the 19.9% dose-reduction rate at 6mg due to TEAEs implies the Phase 3 primary endpoint may be achievable at lower-tolerance doses. A clean Phase 3 primary readout plus Novo-level M&A chatter is the trigger; a Phase 3 miss or significant safety signal is the invalidation.

Agrees with X sentimentThe specialist-holder-position-opening and specific Novo acquisition-candidate framing are grounded. The 1.4% discontinuation / 19.9% dose-reduction nuance is the honest tolerability data worth sizing around.

What to watch: KaiNETIC Phase 3 primary readout, EASD data presentations, cash runway, and any named M&A commentary. Positive Phase 3 primary plus M&A chatter is the trigger; Phase 3 miss or safety signal is the invalidation.

phase3 catalystglp1 space

Read the AI verdict on $KLRA

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech developing injectable and oral gut-hormone receptor agonists targeting obesity and associated metabolic disorders.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $KLRA.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $KLRA

Neutral — Clinical-stage biotech developing injectable and oral gut-hormone receptor agonists targeting obesity and associated metabolic disorders.

Top industry ETF

$IBBiShares Biotechnology ETF
+19.7%YTD
+34.9%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-16.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-24.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-4.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
41.8%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 12, 2026$-1.09$-0.90-21.6%
Q1 2026May 26, 2026$-3650.00$-0.78-470867.7%

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.67$-68.3M

Forward consensus

5-year forecast · up to 4 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$0$0 – $0-$4.21-$5.38 – -$3.300
FY27$0$0 – $0-$4.30-$5.66 – -$2.870
FY28$0$0 – $0-$3.87-$6.21 – -$1.900
FY29$66.9M$66.9M – $66.9M-$3.87-$3.87 – -$3.874
FY30$496.5M$496.5M – $496.5M-$2.70-$2.70 – -$2.703

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.2×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.—Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-29.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.—Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 89.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.6% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.505-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyApr 20Investments, Lp Rtw10% owner500.0K sh$8.0MBuyApr 20Andrew T. KaplanDirector8.4M sh$134.4MBuyApr 20Bain Capital Investors Llc10% owner8.4M sh$134.4MBuyApr 20Adam KoppelDirector1.6M sh$25.0MBuyApr 20Bain Capital Life Sciences Investors, Llc10% owner1.6M sh$25.0M
+ 22 other (15 awards · 6 conversions · 1 exempt) in window

See when $KLRA insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsSep 93
AI summary

Nur Nicholson, Chief Technology Officer at Kailera Therapeutics (KLRA), filed a Form 3 disclosing no initial ownership of company securities. The filing is a routine Section 16 insider reporting disclosure.

3New insider — initial holdingsJul 83
AI summary

Initial Form 3 ownership statement filed by Kathleen Tregoning, a newly reportable officer or director at Kailera Therapeutics, Inc., disclosing initial beneficial ownership of company securities upon becoming a Section 16 reporting person. Routine Section 16(a) disclosure triggered by appointment or election to a qualifying role. No operational implications for the company.

SC 13DActivist position (5%+)Apr 23SC 13D
SC 13DActivist position (5%+)Apr 23SC 13D
8-KCharter amendmentApr 208-K — Item 5.03: Charter amendment · Item 8.01: Other event
424B4Prospectus supplement (offering)Apr 17424B4
3New insider — initial holdingsApr 163
3New insider — initial holdingsApr 163
+ 31 other (18 3s · 3 13Gs · 2 10-Qs · 2 earnings 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Kailera Therapeutics (NASDAQ:KLRA) Sets New 12-Month Low – Time to Sell?defenseworld.net·3d agoKailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meetingglobenewswire.com·7d agoNovo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buyfool.com·7d agoKailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injectionglobenewswire.com·8d agoKailera Therapeutics: An Outside Biotech Bet For The Next GLP-1 Obesity Drug Approvalseekingalpha.com·21d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$KOD$MRNA$IOVA$ARCT$IBRX$VKTX$NWBO$QURE
Voices on X · last 7 days

No standout posts about $KLRA on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport